Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HDM1005. This long-acting agonist targets both the GLP-1 and GIP receptors and is being developed for the treatment of type 2 diabetes (T2D) and weight management in overweight or obese individuals.
Pre-clinical studies indicate that HDM1005, classified as a Category 1 chemical, effectively activates GLP-1 and GIP receptors, thereby promoting insulin release, suppressing appetite, and significantly improving glucose tolerance while lowering blood sugar levels. Additionally, existing data suggests that HDM1005 exhibits favorable medicinal properties and a strong safety profile.- Flcube.com
